# Envisia Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/envisia-therapeutics

- Industry: Biotechnology
- Headquarters: US
- Website: www.envisiatherapeutics.com
- Total disclosed funding: $36M
- Latest round: Series A (Mar 23, 2016)
- Investors on record: 5

## About

Envisia Therapeutics Inc. is focused on developing and commercializing innovative therapeutic solutions for various medical conditions, particularly in chronic pain management and neurological disorders.Founded in 2013, Envisia Therapeutics Inc. specializes in therapeutic innovations aimed at improving patient outcomes. The company is based in the United States and was acquired by Aerie Pharmaceuticals, Inc. in October 2017 for USD 25 mn. The acquisition marked a pivotal moment in the company's trajectory, allowing it to leverage Aerie's resources. The CEO and founder details are currently not specified, and the company has engaged in five funding rounds up until its latest deal date of October 5, 2017.Envisia Therapeutics specializes in the development and commercialization of innovative therapeutic solutions targeting various medical conditions. Their core product offerings include advanced therapeutic interventions designed to improve patient outcomes in areas such as chronic pain management and neurological disorders. These products employ technology and research methodologies, focusing on personalized medicine to address specific patient needs. Envisia Therapeutics primarily serves healthcare providers, including hospitals and specialty clinics, as well as patients seeking effective treatment options. The company markets its products across North America and Europe, ensuring a wide reach to healthcare professionals and end-users in these geographical regions.Envisia Therapeutics generates revenue through direct sales of its therapeutic products and subscription-based services for healthcare providers. The company’s transactions are structured primarily as B2B engagements, where healthcare institutions purchase their offerings directly for integration into patient care programs. Pricing agreements are often negotiated based on volume with large healthcare networks. Specific pricing plans reflect the unique service needs of healthcare providers, which contributes to sustained revenue growth through repeat business and positive patient outcomes.Following its acquisition in October 2017, Envisia Therapeutics plans to leverage Aerie Pharmaceuticals' capabilities to enhance its product portfolio. The upcoming rollout of new therapeutic solutions is anticipated, though specific launch dates have not been disclosed. The company aims to expand into additional European markets and increase its presence in North America, with targeted initiatives planned for the next few years. The funding received from the acquisition will be crucial in supporting these growth strategies, ensuring the development of new products and market expansion initiatives.

## Funding rounds

- Series A, Mar 23, 2016, $17M — New Enterprise Associates, Canaan Partners, Pappas Capital, Wakefield Group, 5Y Capital
- Series A, Apr 1, 2015, $4.8M — Canaan Partners, Pappas Capital
- Series A, Nov 21, 2013, $15M — New Enterprise Associates, Canaan Partners, Pappas Capital, Wakefield Group, 5Y Capital

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A
- Pappas Capital (https://capitalatlas.ai/funds/pappas-capital) — Series A
- Wakefield Group (https://capitalatlas.ai/funds/wakefield-group) — Series A
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series A